Home・Lista de Ações・Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc

Abrir

SetorSaúde

26.81

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

26.01

Máximo

27.12

Indicadores-chave
By Trading Economics
Rendimento	93M -92M
Vendas	78M 214M
EPS	-0.9
Margem de lucro	-42.991
Funcionários	1,371
EBITDA	94M -61M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+88.91% upside

Dividendos
By Acuity
Próximos Ganhos	3 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	178M 2.6B
Abertura anterior	26.81
Fecho anterior	26.81

Sentimento de Notícias

By Acuity

50%

135 / 340 Ranking em Healthcare

Ultragenyx Pharmaceutical Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de ago. de 2026, 19:36 UTC

News

Ultragenyx Pharmaceutical reached a settlement with Esjay Pharma over DOJOLVI patent litigation, allowing a generic version to launch in 2023. Shares are higher today.

10 de ago. de 2026, 19:16 UTC

News

HC Wainwright reiterated its Buy rating on Ultragenyx Pharmaceutical, maintaining a $50 price target, contributing to shares trading higher during the session.

7 de ago. de 2026, 20:03 UTC

News

Ultragenyx Pharmaceutical reported a loss of -$0.90 per share, beating estimates. Revenue of $214 million also exceeded expectations, but shares are trading roughly flat.

6 de ago. de 2026, 23:21 UTC

Ultragenyx Pharmaceutical Inc shares are higher in after-market trading, showing unusual strength despite remaining below their 20-day moving average.

5 de ago. de 2026, 19:52 UTC

News

Ultragenyx shares are lower after Wells Fargo cut its price target to $45. The company reported an EPS loss of $0.90, exceeding expectations.

4 de ago. de 2026, 23:02 UTC

News

Ultragenyx Pharmaceutical reported second-quarter revenue of $214 million and narrowed its net loss to $92 million, with shares trading higher in after-market hours.

3 de ago. de 2026, 22:51 UTC

Ultragenyx Pharmaceutical shares are trading roughly flat after-market. The stock is down significantly compared to its month-ago close and below its 20-day moving average.

31 de jul. de 2026, 19:52 UTC

Correlated Moves

Ultragenyx Pharmaceutical is lower today amid a decline in the Biotechnology sub-sector, with shares near the lower end of their one-month range.

30 de jul. de 2026, 19:58 UTC

Correlated Moves

Ultragenyx rises, supported by SPDR S&P Biotech ETF gains.

29 de jul. de 2026, 18:43 UTC

Ultragenyx Pharmaceutical is lower today, continuing a decline amid broader market pressures from rising crude oil prices and geopolitical tensions.

28 de jul. de 2026, 19:03 UTC

Ultragenyx Pharmaceutical Inc shares are trading lower, reflecting a challenging performance backdrop amid strength in U.S. mega-cap stocks. No specific news was identified.

27 de jul. de 2026, 19:07 UTC

Ultragenyx Pharmaceutical Inc shares are higher as crude oil prices decline, easing geopolitical concerns. No specific company news was identified for the move.

24 de jul. de 2026, 19:51 UTC

Ultragenyx Pharmaceutical Inc shares are declining, continuing a trend of lower daily closes. Broader market volatility and new tariffs may be contributing factors.

22 de jul. de 2026, 19:36 UTC

Ultragenyx Pharmaceutical shares are declining amid rising crude oil prices due to U.S.-Iran tensions. The stock remains below its 20-day moving average.

21 de jul. de 2026, 19:22 UTC

Correlated Moves

Rising amid broader market gains and SPDR S&P Biotech support.

20 de jul. de 2026, 19:17 UTC

Correlated Moves

Ultragenyx Pharmaceutical is declining amid a broader downturn in the Biotechnology sector, continuing a trend of seven consecutive lower sessions.

Comparação entre Pares

Variação de preço

Ultragenyx Pharmaceutical Inc Previsão

Preço-alvo

By TipRanks

88.91% parte superior

Previsão para 12 meses

Média 50.93 USD 88.91%

Máximo 96 USD

Mínimo 27 USD

Com base em 15 analistas de Wall Street que oferecem metas de preço de 12 meses para Ultragenyx Pharmaceutical Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

15 ratings

Comprar

Manter

Vender

Com base em 15 analistas que deram avaliações de ações para Ultragenyx Pharmaceutical Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

135 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.